Skip to main content

Sterling enters second investment phase

CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.

Enzymaster heads for North America

Enzymatic biocatalyst specialist Enzymaster is to create a formal presence in the US, aided by business management consultancy Haig Barrett, which specialises in the life sciences and speciality chemicals. This will soon include facilities in the US, the company said.

Enzymaster is now launching business relationship models to address the specific needs of the North American market. These include fee-for-service models with client-centric IP constructs, development programmes including commercial manufacturing of engineered enzymes and collaborative engineering partnerships.

Novozymes enters biocontrol sector

Enzymes giant Novozymes has revealed that it is diversifying into biocontrol in agriculture. The company said that it sees this emerging sector as having huge growth potential, as pests continue to cause billions of dollars in damage to crops every year while pressure is continuing to restrict the use of chemical pesticides.

Subscribe to enzymes